Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions - Report - MDSpire

Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions

  • By

  • Chuying Yu

  • Xintong Ye

  • Haoyu Zhao

  • Suting Qian

  • Feifei Xie

  • Qingsheng Liu

  • June 4, 2026

  • 0 min

Share

Clinical Report: Bile Acids: Their Role in Health and Disease

Overview

This review highlights the dual roles of bile acids (BAs) in metabolism and immune regulation, emphasizing their structural diversity and the impact of microbiota-driven modifications. Emerging therapeutic strategies targeting BA signaling pathways show potential for treating various metabolic and neoplastic diseases.

Background

Bile acids are essential for lipid digestion and serve as signaling molecules that regulate metabolic homeostasis and immune responses. Their synthesis and modification are influenced by both host and gut microbiota, linking dysbiosis to metabolic disorders and inflammatory diseases. Understanding these mechanisms is crucial for developing targeted therapies.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

Rephrase findings for clarity and ensure they are directly supported by the source.

Clinical Implications

Healthcare professionals should consider the role of bile acids in metabolic regulation and their potential as therapeutic targets. Interventions that modify bile acid signaling pathways may offer new treatment options for metabolic and inflammatory diseases.

Conclusion

Specify areas of ongoing research that are critical for future therapeutic applications.

Related Resources & Content

  1. Journal of Gastroenterology, 2020 -- Novel Treatment Approaches for Primary Biliary Cholangitis
  2. Frontiers in Immunology, 2026 -- Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases
  3. The Journal of Infectious Diseases, 2023 -- Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid β-Oxidation
  4. Archives of Toxicology, 2025 -- Investigating Drug-Induced Cholestatic Liver Injury Through Cell-Based Methodologies
  5. Primary Biliary Cholangitis | AASLD, 2026
  6. Novel Drug Approvals for 2026 | FDA
  7. EASL Clinical Practice Guidelines on sclerosing cholangitis - ScienceDirect
  8. Primary Biliary Cholangitis | AASLD
  9. Novel Drug Approvals for 2026 | FDA
  10. EASL Clinical Practice Guidelines on sclerosing cholangitis - ScienceDirect

Original Source(s)

Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions

  • by Chuying Yu, Xintong Ye, Haoyu Zhao, Suting Qian, Feifei Xie, Qingsheng Liu

  • June 4, 2026

Related Content

The role of intestinal microbiota in the pathogenesis of childhood asthma

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.